Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: GJC1 (ImmuneEditome ID:10052)

1. Gene summary of enriched editing regions for GJC1

Gene summary

Gene information	Gene symbol	GJC1
	Gene ID	10052
	GeneSynonyms	CX45\|GJA7
	GeneCytomap	17q21.31
	GeneType	protein-coding
	GeneDescription	gap junction gamma-1 protein\|CTC-296K1.4\|connexin-45\|gap junction alpha-7 protein\|gap junction protein, gamma 1, 45kDa
	GeneModificationdate	20230517
	UniprotID	P36383;Q5H9P2;K7EM78;K7ENT9;K7EQ14
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr17:44798876-44803011:-	ENST00000426548.4	ENSG00000182963.8	GJC1	UTR3	AluJb,AluSz6,AluSx3,AluJo,AluSz,AluSq2,AluSx1	chr17:44798876-44803011:-.alignment
chr17:44798876-44803011:-	ENST00000587113.1	ENSG00000182963.8	GJC1	UTR3	AluJb,AluSz6,AluSx3,AluJo,AluSz,AluSq2,AluSx1	chr17:44798876-44803011:-.alignment
chr17:44798876-44803011:-	ENST00000590758.2	ENSG00000182963.8	GJC1	UTR3	AluJb,AluSz6,AluSx3,AluJo,AluSz,AluSq2,AluSx1	chr17:44798876-44803011:-.alignment
chr17:44810885-44812312:-	ENST00000426548.4	ENSG00000182963.8	GJC1	intronic	AluSc8,AluJb,AluSq2	chr17:44810885-44812312:-.alignment
chr17:44810885-44812312:-	ENST00000586267.1	ENSG00000182963.8	GJC1	intronic	AluSc8,AluJb,AluSq2	chr17:44810885-44812312:-.alignment
chr17:44810885-44812312:-	ENST00000587239.4	ENSG00000182963.8	GJC1	intronic	AluSc8,AluJb,AluSq2	chr17:44810885-44812312:-.alignment
chr17:44810885-44812312:-	ENST00000590758.2	ENSG00000182963.8	GJC1	intronic	AluSc8,AluJb,AluSq2	chr17:44810885-44812312:-.alignment
chr17:44810885-44812312:-	ENST00000591424.4	ENSG00000182963.8	GJC1	intronic	AluSc8,AluJb,AluSq2	chr17:44810885-44812312:-.alignment
chr17:44810885-44812312:-	ENST00000592524.4	ENSG00000182963.8	GJC1	intronic	AluSc8,AluJb,AluSq2	chr17:44810885-44812312:-.alignment

Top

2. Tumor-specific enriched editing regions for GJC1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr17:44798876-44803011:-	KIRC	EER	2.1007e-04
ENSG00000182963.8,GJC1	KIRC	EAG	2.1119e-04
chr17:44798876-44803011:-	PRAD	EER	3.2349e-06
ENSG00000182963.8,GJC1	PRAD	EAG	3.2274e-06
chr17:44798876-44803011:-	UCEC	EER	2.4789e-14
ENSG00000182963.8,GJC1	UCEC	EAG	2.4079e-14

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000182963.8,GJC1	READ	Path	EAG	1.3260e-03	8.8768e-03	-0.5327
chr17:44798876-44803011:-	READ	Path	EER	1.3260e-03	8.8768e-03	-0.5327

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr17:44798876-44803011:-	CESC	EER	4.8537e-03	1.6759e-03	1.8447e-05
ENSG00000182963.8,GJC1	CESC	EAG	4.8537e-03	1.6759e-03	1.8447e-05
chr17:44798876-44803011:-	CHOL	EER	7.7228e-05	8.3362e-03	2.9626e-10
ENSG00000182963.8,GJC1	CHOL	EAG	7.7228e-05	8.3362e-03	2.9626e-10

Top

3. Enriched editing regions and immune related genes for GJC1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr17:44798876-44803011:-

GBM

EER

ENSG00000184068,RP5-821D11.7

-0.3954

1.3430e-04

7.2713e-08

-0.4054

IGF2BP2;NOP56

T_cells_follicular_helper

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr17:44798876-44803011:-

GBM

EER

ENSG00000172007,RAB33B

0.3642

5.0108e-04

1.0211e-07

0.4011

EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10

T_cells_gamma_delta

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr17:44798876-44803011:-

GBM

EER

ENSG00000164117,FBXO8

0.3127

5.0055e-03

2.1135e-08

0.4203

CELF2;EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TARDBP

Macrophages_M0

GSVA_HALLMARK_FATTY_ACID_METABOLISM

chr17:44798876-44803011:-

GBM

EER

ENSG00000134970,TMED7

0.2950

8.8240e-03

8.8072e-08

0.4030

CELF2;EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TARDBP

T_cells_follicular_helper

GSVA_HALLMARK_PROTEIN_SECRETION

chr17:44798876-44803011:-

GBM

EER

ENSG00000184068,RP5-821D11.7

-0.3954

1.3430e-04

7.2713e-08

-0.4054

IGF2BP2;NOP56

T_cells_follicular_helper

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr17:44798876-44803011:-

GBM

EER

ENSG00000172007,RAB33B

0.3642

5.0108e-04

1.0211e-07

0.4011

EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10

T_cells_gamma_delta

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr17:44798876-44803011:-

GBM

EER

ENSG00000164117,FBXO8

0.3127

5.0055e-03

2.1135e-08

0.4203

CELF2;EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TARDBP

Macrophages_M0

GSVA_HALLMARK_FATTY_ACID_METABOLISM

chr17:44798876-44803011:-

GBM

EER

ENSG00000134970,TMED7

0.2950

8.8240e-03

8.8072e-08

0.4030

CELF2;EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TARDBP

T_cells_follicular_helper

GSVA_HALLMARK_PROTEIN_SECRETION

chr17:44798876-44803011:-

GBM

EER

ENSG00000184068,RP5-821D11.7

-0.3954

1.3430e-04

7.2713e-08

-0.4054

IGF2BP2;NOP56

T_cells_follicular_helper

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr17:44798876-44803011:-

GBM

EER

ENSG00000172007,RAB33B

0.3642

5.0108e-04

1.0211e-07

0.4011

EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10

T_cells_gamma_delta

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr17:44798876-44803011:-

GBM

EER

ENSG00000164117,FBXO8

0.3127

5.0055e-03

2.1135e-08

0.4203

CELF2;EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TARDBP

Macrophages_M0

GSVA_HALLMARK_FATTY_ACID_METABOLISM

chr17:44798876-44803011:-

GBM

EER

ENSG00000134970,TMED7

0.2950

8.8240e-03

8.8072e-08

0.4030

CELF2;EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TARDBP

T_cells_follicular_helper

GSVA_HALLMARK_PROTEIN_SECRETION

More results

Top

4. Enriched editing regions and immune related splicing for GJC1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr17:44798876-44803011:-

GBM

EER

ENSG00000178922.12

chr1

43451152:43452319:43452902:43453004

-0.2868

4.0654e-02

5.1363e-08

-0.4143

EIF4A3;FBL;FUS;HNRNPA2B1;NOP58;RBFOX2;RBM10;TARDBP

Macrophages_M2

GSVA_HALLMARK_ADIPOGENESIS

ENSG00000182963.8,GJC1

GBM

EAG

ENSG00000178922.12

chr1

43451152:43452319:43452902:43453004

-0.2868

4.7044e-02

5.0312e-08

-0.4146

ADAR;AIFM1;CNBP;CSTF2T;DGCR8;EIF4A3;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP58;NUMA1;RANGAP1;RBFOX2;RBM10;RNF219;SRSF1;SRSF3;TAF15;TARDBP;U2AF2;UPF1;YTHDC1;ZNF184

Macrophages_M2

GSVA_HALLMARK_ADIPOGENESIS

chr17:44798876-44803011:-

GBM

EER

ENSG00000178149.12

chr3

49015487:49015872:49015972:49016033

-0.3428

7.1696e-03

6.8590e-08

-0.4061

EIF4A3;FBL;FUS;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPUL1;IGF2BP2;NOP56;NOP58;PTBP1;RBFOX2;RBM10;TARDBP

T_cells_CD4_memory_activated

GSVA_HALLMARK_ADIPOGENESIS

ENSG00000182963.8,GJC1

GBM

EAG

ENSG00000178149.12

chr3

49015487:49015872:49015972:49016033

-0.3428

8.3602e-03

6.7730e-08

-0.4062

ACIN1;ADAR;AIFM1;BUD13;CPSF6;CSTF2T;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;NUMA1;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF2;UPF1;YTHDC1;ZNF184

T_cells_CD4_memory_activated

GSVA_HALLMARK_ADIPOGENESIS

More results

Top

5. Enriched editing regions and immune infiltration for GJC1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr17:44798876-44803011:-	BRCA	EER	T_cells_CD4_memory_resting	1.7219e-03	0.1093
ENSG00000182963.8,GJC1	BRCA	EAG	T_cells_CD4_memory_resting	1.7217e-03	0.1093
chr17:44798876-44803011:-	CESC	EER	Macrophages_M2	8.4575e-03	-0.2002
ENSG00000182963.8,GJC1	CESC	EAG	Macrophages_M2	8.4575e-03	-0.2002
chr17:44798876-44803011:-	CHOL	EER	Mast_cells_activated	3.6531e-02	0.4201
ENSG00000182963.8,GJC1	CHOL	EAG	Mast_cells_activated	3.6531e-02	0.4201
chr17:44798876-44803011:-	COAD	EER	Mast_cells_activated	7.1548e-03	0.3653
ENSG00000182963.8,GJC1	COAD	EAG	Mast_cells_activated	7.1548e-03	0.3653
chr17:44798876-44803011:-	ESCA	EER	B_cells_memory	3.7833e-02	0.1810
ENSG00000182963.8,GJC1	ESCA	EAG	B_cells_memory	2.1880e-02	0.1994
chr17:44798876-44803011:-	GBM	EER	Macrophages_M0	3.8175e-02	-0.1620
ENSG00000182963.8,GJC1	GBM	EAG	Macrophages_M0	3.8722e-02	-0.1616
chr17:44798876-44803011:-	HNSC	EER	T_cells_CD4_memory_resting	4.6742e-02	0.1099
ENSG00000182963.8,GJC1	HNSC	EAG	T_cells_CD4_memory_resting	4.6761e-02	0.1099
chr17:44798876-44803011:-	KICH	EER	Dendritic_cells_activated	1.1532e-02	0.4478
ENSG00000182963.8,GJC1	KICH	EAG	Dendritic_cells_activated	1.1531e-02	0.4478
chr17:44798876-44803011:-	KIRC	EER	Dendritic_cells_resting	2.4315e-03	0.1595
ENSG00000182963.8,GJC1	KIRC	EAG	Dendritic_cells_resting	2.4384e-03	0.1595
chr17:44798876-44803011:-	KIRP	EER	Dendritic_cells_activated	9.3104e-05	0.5662
ENSG00000182963.8,GJC1	KIRP	EAG	Dendritic_cells_activated	9.3104e-05	0.5662
chr17:44798876-44803011:-	LGG	EER	Mast_cells_activated	1.2065e-03	0.2009
ENSG00000182963.8,GJC1	LGG	EAG	Mast_cells_activated	1.2065e-03	0.2009
chr17:44798876-44803011:-	LIHC	EER	T_cells_regulatory_(Tregs)	1.8505e-02	-0.2565
ENSG00000182963.8,GJC1	LIHC	EAG	T_cells_regulatory_(Tregs)	1.8505e-02	-0.2565
chr17:44798876-44803011:-	LUSC	EER	T_cells_regulatory_(Tregs)	2.9147e-02	0.1254
ENSG00000182963.8,GJC1	LUSC	EAG	T_cells_regulatory_(Tregs)	2.9166e-02	0.1253
chr17:44798876-44803011:-	PAAD	EER	T_cells_CD8	5.6474e-03	-0.2776
ENSG00000182963.8,GJC1	PAAD	EAG	T_cells_CD8	5.6474e-03	-0.2776
chr17:44798876-44803011:-	PCPG	EER	T_cells_gamma_delta	3.0353e-02	0.1954
ENSG00000182963.8,GJC1	PCPG	EAG	T_cells_gamma_delta	3.0353e-02	0.1954
chr17:44798876-44803011:-	PRAD	EER	Macrophages_M2	1.6856e-03	-0.1785
ENSG00000182963.8,GJC1	PRAD	EAG	Macrophages_M2	1.6844e-03	-0.1785
chr17:44798876-44803011:-	SKCM	EER	T_cells_CD4_memory_resting	6.0902e-03	-0.1300
ENSG00000182963.8,GJC1	SKCM	EAG	T_cells_CD4_memory_resting	6.0118e-03	-0.1302
chr17:44798876-44803011:-	STAD	EER	NK_cells_resting	2.8483e-03	0.1906
ENSG00000182963.8,GJC1	STAD	EAG	NK_cells_resting	2.6437e-03	0.1913
chr17:44798876-44803011:-	TGCT	EER	Dendritic_cells_resting	1.6240e-02	-0.1934
ENSG00000182963.8,GJC1	TGCT	EAG	Dendritic_cells_resting	1.6192e-02	-0.1935
chr17:44798876-44803011:-	THCA	EER	NK_cells_activated	2.8685e-02	-0.1108
ENSG00000182963.8,GJC1	THCA	EAG	NK_cells_activated	2.8685e-02	-0.1108
chr17:44798876-44803011:-	THYM	EER	Neutrophils	3.0615e-02	0.2973
ENSG00000182963.8,GJC1	THYM	EAG	Neutrophils	3.0615e-02	0.2973
chr17:44798876-44803011:-	UCS	EER	Neutrophils	3.2010e-02	0.2950
ENSG00000182963.8,GJC1	UCS	EAG	Neutrophils	3.2014e-02	0.2950

Top

6. Enriched editing regions and immune gene sets for GJC1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr17:44798876-44803011:-	ACC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.4443e-03	0.4759
ENSG00000182963.8,GJC1	ACC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.4443e-03	0.4759
ENSG00000182963.8,GJC1	BLCA	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	1.2650e-03	0.1967
chr17:44798876-44803011:-	BLCA	GSVA_HALLMARK_NOTCH_SIGNALING	EER	1.2305e-03	0.1971
chr17:44798876-44803011:-	BRCA	GSVA_HALLMARK_SPERMATOGENESIS	EER	1.6323e-03	-0.1098
ENSG00000182963.8,GJC1	BRCA	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.6318e-03	-0.1098
ENSG00000182963.8,GJC1	CESC	GSVA_HALLMARK_DNA_REPAIR	EAG	3.0797e-04	-0.2719
chr17:44798876-44803011:-	CESC	GSVA_HALLMARK_DNA_REPAIR	EER	3.0797e-04	-0.2719
ENSG00000182963.8,GJC1	CHOL	GSVA_HALLMARK_ANGIOGENESIS	EAG	1.4437e-02	-0.4831
chr17:44798876-44803011:-	CHOL	GSVA_HALLMARK_ANGIOGENESIS	EER	1.4437e-02	-0.4831
ENSG00000182963.8,GJC1	GBM	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	2.4403e-04	0.2828
chr17:44798876-44803011:-	GBM	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	2.4729e-04	0.2825
chr17:44798876-44803011:-	HNSC	GSVA_HALLMARK_DNA_REPAIR	EER	4.4214e-02	-0.1112
ENSG00000182963.8,GJC1	HNSC	GSVA_HALLMARK_DNA_REPAIR	EAG	4.4130e-02	-0.1112
chr17:44798876-44803011:-	KICH	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.0142e-02	-0.4549
ENSG00000182963.8,GJC1	KICH	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.0163e-02	-0.4548
chr17:44798876-44803011:-	KIRC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.4763e-05	-0.2265
ENSG00000182963.8,GJC1	KIRC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.3808e-05	-0.2272
ENSG00000182963.8,GJC1	KIRP	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.5772e-02	-0.3438
chr17:44798876-44803011:-	KIRP	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.5772e-02	-0.3438
ENSG00000182963.8,GJC1	LGG	GSVA_HALLMARK_E2F_TARGETS	EAG	7.1102e-08	-0.3284
chr17:44798876-44803011:-	LGG	GSVA_HALLMARK_E2F_TARGETS	EER	7.1102e-08	-0.3284
ENSG00000182963.8,GJC1	LIHC	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	8.2185e-03	-0.2866
chr17:44798876-44803011:-	LIHC	GSVA_HALLMARK_UV_RESPONSE_UP	EER	8.2185e-03	-0.2866
chr17:44798876-44803011:-	LUSC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.6325e-05	-0.2448
ENSG00000182963.8,GJC1	LUSC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.6327e-05	-0.2448
chr17:44798876-44803011:-	MESO	GSVA_HALLMARK_SPERMATOGENESIS	EER	3.3978e-02	0.2891
ENSG00000182963.8,GJC1	MESO	GSVA_HALLMARK_SPERMATOGENESIS	EAG	3.3984e-02	0.2891
ENSG00000182963.8,GJC1	OV	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	1.3606e-03	0.2891
chr17:44798876-44803011:-	OV	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	1.3824e-03	0.2887
chr17:44798876-44803011:-	PAAD	GSVA_HALLMARK_MYOGENESIS	EER	1.8590e-03	-0.3105
ENSG00000182963.8,GJC1	PAAD	GSVA_HALLMARK_MYOGENESIS	EAG	1.8590e-03	-0.3105
ENSG00000182963.8,GJC1	PCPG	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	5.0230e-04	0.3092
chr17:44798876-44803011:-	PCPG	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	5.0230e-04	0.3092
ENSG00000182963.8,GJC1	PRAD	GSVA_HALLMARK_MYOGENESIS	EAG	1.5922e-05	-0.2436
chr17:44798876-44803011:-	PRAD	GSVA_HALLMARK_MYOGENESIS	EER	1.5990e-05	-0.2435
chr17:44798876-44803011:-	SARC	GSVA_HALLMARK_HEME_METABOLISM	EER	1.8601e-02	0.1491
ENSG00000182963.8,GJC1	SARC	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.9382e-02	0.1481
ENSG00000182963.8,GJC1	SKCM	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	9.6320e-04	-0.1561
chr17:44798876-44803011:-	SKCM	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	9.6778e-04	-0.1561
ENSG00000182963.8,GJC1	STAD	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	1.5814e-08	0.3513
chr17:44798876-44803011:-	STAD	GSVA_HALLMARK_MTORC1_SIGNALING	EER	3.8477e-08	0.3436
ENSG00000182963.8,GJC1	TGCT	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	3.1977e-02	0.1729
chr17:44798876-44803011:-	TGCT	GSVA_HALLMARK_UV_RESPONSE_DN	EER	3.1919e-02	0.1730
chr17:44798876-44803011:-	THCA	GSVA_HALLMARK_G2M_CHECKPOINT	EER	5.0500e-04	0.1753
ENSG00000182963.8,GJC1	THCA	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	5.0500e-04	0.1753
ENSG00000182963.8,GJC1	THYM	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	5.7660e-03	-0.3743
chr17:44798876-44803011:-	THYM	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	5.7660e-03	-0.3743
ENSG00000182963.8,GJC1	UCEC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.8894e-02	-0.2761
chr17:44798876-44803011:-	UCEC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.8894e-02	-0.2761
ENSG00000182963.8,GJC1	UCS	GSVA_HALLMARK_DNA_REPAIR	EAG	1.3387e-04	-0.5008
chr17:44798876-44803011:-	UCS	GSVA_HALLMARK_DNA_REPAIR	EER	1.3372e-04	-0.5008

Top

7. Enriched editing regions and drugs for GJC1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000182963.8,GJC1	ACC	GW843682X	EAG	1.3128e-03	0.4795
chr17:44798876-44803011:-	ACC	GW843682X	EER	1.3128e-03	0.4795
ENSG00000182963.8,GJC1	BLCA	AKT.inhibitor.VIII	EAG	1.5154e-03	-0.1935
chr17:44798876-44803011:-	BLCA	AKT.inhibitor.VIII	EER	1.5355e-03	-0.1933
chr17:44798876-44803011:-	BRCA	BI.D1870	EER	3.1602e-04	0.1255
ENSG00000182963.8,GJC1	BRCA	BI.D1870	EAG	3.1589e-04	0.1255
ENSG00000182963.8,GJC1	CESC	Cytarabine	EAG	6.8926e-05	0.2987
chr17:44798876-44803011:-	CESC	Cytarabine	EER	6.8926e-05	0.2987
ENSG00000182963.8,GJC1	CHOL	KU.55933	EAG	1.5208e-03	0.6000
chr17:44798876-44803011:-	CHOL	KU.55933	EER	1.5208e-03	0.6000
ENSG00000182963.8,GJC1	COAD	AKT.inhibitor.VIII	EAG	7.5716e-03	-0.3629
chr17:44798876-44803011:-	COAD	AKT.inhibitor.VIII	EER	7.5716e-03	-0.3629
chr17:44798876-44803011:-	DLBC	Bicalutamide	EER	1.9562e-02	-0.5049
ENSG00000182963.8,GJC1	DLBC	Bicalutamide	EAG	1.9562e-02	-0.5049
chr17:44798876-44803011:-	ESCA	Axitinib	EER	1.4084e-02	0.2141
ENSG00000182963.8,GJC1	ESCA	Axitinib	EAG	1.6792e-02	0.2086
chr17:44798876-44803011:-	GBM	Bosutinib	EER	2.3962e-03	0.2355
ENSG00000182963.8,GJC1	GBM	Bosutinib	EAG	2.3959e-03	0.2355
ENSG00000182963.8,GJC1	HNSC	GSK.650394	EAG	4.9027e-03	0.1550
chr17:44798876-44803011:-	HNSC	GSK.650394	EER	4.8900e-03	0.1550
chr17:44798876-44803011:-	KICH	EHT.1864	EER	2.0798e-02	-0.4134
ENSG00000182963.8,GJC1	KICH	EHT.1864	EAG	2.0950e-02	-0.4130
chr17:44798876-44803011:-	KIRC	AZD.0530	EER	5.1727e-09	0.3021
ENSG00000182963.8,GJC1	KIRC	AZD.0530	EAG	4.7310e-09	0.3028
ENSG00000182963.8,GJC1	KIRP	IPA.3	EAG	1.1807e-02	0.3850
chr17:44798876-44803011:-	KIRP	IPA.3	EER	1.1807e-02	0.3850
chr17:44798876-44803011:-	LGG	GSK269962A	EER	1.8099e-07	0.3191
ENSG00000182963.8,GJC1	LGG	GSK269962A	EAG	1.8099e-07	0.3191
ENSG00000182963.8,GJC1	LIHC	BMS.536924	EAG	1.7046e-02	0.2597
chr17:44798876-44803011:-	LIHC	BMS.536924	EER	1.7046e-02	0.2597
chr17:44798876-44803011:-	LUSC	Embelin	EER	6.1683e-03	0.1570
ENSG00000182963.8,GJC1	LUSC	Embelin	EAG	6.1851e-03	0.1570
chr17:44798876-44803011:-	OV	CGP.60474	EER	5.6691e-04	-0.3101
ENSG00000182963.8,GJC1	OV	CGP.60474	EAG	5.7955e-04	-0.3096
chr17:44798876-44803011:-	PAAD	GDC0941	EER	2.4674e-03	0.3025
ENSG00000182963.8,GJC1	PAAD	GDC0941	EAG	2.4674e-03	0.3025
chr17:44798876-44803011:-	PCPG	CEP.701	EER	7.2418e-07	0.4293
ENSG00000182963.8,GJC1	PCPG	CEP.701	EAG	7.2418e-07	0.4293
ENSG00000182963.8,GJC1	PRAD	GSK269962A	EAG	1.6185e-05	0.2434
chr17:44798876-44803011:-	PRAD	GSK269962A	EER	1.6139e-05	0.2434
chr17:44798876-44803011:-	READ	KU.55933	EER	3.2067e-03	0.5874
ENSG00000182963.8,GJC1	READ	KU.55933	EAG	3.2067e-03	0.5874
ENSG00000182963.8,GJC1	SARC	Dasatinib	EAG	5.4667e-04	0.2188
chr17:44798876-44803011:-	SARC	Dasatinib	EER	5.4669e-04	0.2188
chr17:44798876-44803011:-	SKCM	AZD6244	EER	3.4654e-06	-0.2182
ENSG00000182963.8,GJC1	SKCM	AZD6244	EAG	3.4629e-06	-0.2182
ENSG00000182963.8,GJC1	STAD	CCT007093	EAG	6.1445e-09	0.3606
chr17:44798876-44803011:-	STAD	AP.24534	EER	6.1341e-09	0.3620
chr17:44798876-44803011:-	THCA	AMG.706	EER	1.1548e-06	0.2433
ENSG00000182963.8,GJC1	THCA	AMG.706	EAG	1.1548e-06	0.2433
ENSG00000182963.8,GJC1	THYM	Gemcitabine	EAG	1.2038e-02	0.3426
chr17:44798876-44803011:-	THYM	Gemcitabine	EER	1.2038e-02	0.3426
ENSG00000182963.8,GJC1	UCEC	DMOG	EAG	2.9491e-07	0.5611
chr17:44798876-44803011:-	UCEC	DMOG	EER	2.9491e-07	0.5611
chr17:44798876-44803011:-	UCS	DMOG	EER	6.5745e-04	-0.4531
ENSG00000182963.8,GJC1	UCS	DMOG	EAG	6.5817e-04	-0.4530

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType